%0 Journal Article
%T Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study
%A Jan L£¿tvall
%A Mona Palmqvist
%A Peter Arvidsson
%J Clinical and Translational Allergy
%D 2011
%I BioMed Central
%R 10.1186/2045-7022-1-12
%X Twelve patients with documented early and late asthmatic responses (EAR and LAR) to inhaled allergen at a screening visit were randomized in a double-blind fashion to treatment with mometasone (200 ¦Ìg ¡Á 2 or 400 ¦Ìg ¡Á 2), budesonide (400 ¦Ìg ¡Á 2) or placebo in a double-blind crossover fashion for a period of seven days. Challenge with the total allergen dose causing both an EAR and LAR was given on the last day of treatment taken in the morning. Lung function was assessed using FEV1, and systemic glucocorticoid activity was quantified using 24 h urinary cortisol.Mometasone and budesonide attenuate both EAR and LAR to allergen to a similar degree. No significant dose-related effects on the lung function parameters were observed. Both treatments reduced the relative amount of sputum eosinophils (%) after allergen. At the dose of 800 ¦Ìg daily, mometasone reduced 24 h urinary cortisol by approximately 35%. Both drugs were well tolerated.Mometasone and budesonide are equieffective in reducing early and late asthmatic responses induced by inhaled allergen challenge. Mometasone 800 ¦Ìg given for seven days partially affects the HPA axis.Asthmatic patients with allergies often develop early (EAR) and in some patients also a late asthmatic response (LAR) when a relevant allergen is inhaled [1-3]. Allergen exposure can also increase non-specific bronchial hyperresponsiveness to stimuli such as methacholine or histamine [4]. The LAR and the bronchial hyperresponsiveness are often associated with increase of eosinophils in the blood, and influx of eosinophils into the airways [3,5].The anti-inflammatory effects of inhaled glucocorticoids in asthma are well documented [1,6,7], shown by attenuation of the EAR, LAR and allergen-induced sputum eosinophils. Glucocorticoids are also more effective than anti-leukotrienes in attenuating the LARs and improve the bronchial hyperresponsiveness in mild asthmatic patients [8]. Mometasone and budesonide are corticosteroids that have been shown
%K allergen
%K asthma
%K budesonide
%K mometasone
%K inflammation
%U http://www.ctajournal.com/content/1/1/12